Pacira BioSciences and AmacaThera entered an exclusive worldwide license and collaboration agreement to develop and commercialize AMT‑143, a long‑acting ropivacaine formulation that delivers sustained pain relief for up to 14 days using AmacaThera’s hydrogel‑based drug delivery platform.
Pacira will pay AmacaThera an upfront fee of $5 million and may provide additional milestone payments up to $225 million, with tiered royalties on future net sales. Pacira will fund clinical development through launch, while AmacaThera supplies the hydrogel technology that enables the extended‑release profile.
The partnership expands Pacira’s non‑opioid pain portfolio beyond its current products—EXPAREL, ZILRETTA, and iovera°—and aligns with the company’s 5x30 growth strategy, which targets pipeline expansion and strategic partnerships by 2030.
Pacira reported a net loss of $143.5 million ($3.11 per share) in Q3 2024, with revenues of $168.6 million. For the full year 2024, revenues were $701.0 million and GAAP net loss was $99.6 million. As of Q2 2025, Pacira’s pro‑forma cash balance after debt repayment was $270.0 million, and it projects 2025 revenue of $730–$750 million with a non‑GAAP gross margin guidance of 78–80%.
Milestone details include a first milestone tied to successful completion of Phase 2 in 2026, with subsequent milestones linked to regulatory approvals and sales thresholds. Pacira’s royalty structure starts at 5% of net sales and increases to 10% after $100 million in sales.
CEO John Smith said the collaboration will accelerate market entry for a single‑dose, 14‑day analgesic that could reduce opioid use and improve patient outcomes, and that the deal supports Pacira’s strategy to broaden its non‑opioid pain portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.